Seagen's highest selling drug snags a label expansion for pediatric cancer patients

Seagen’s top-selling drug just scored another indication, a few weeks after execs boosted their full-year sales expectations.

The company’s Takeda-partnered antibody drug conjugate Adcetris is now available to pediatric patients 2 years and older with previously untreated high-risk classical Hodgkin’s lymphoma (cHL), in combination with a standard-of-care chemotherapy regimen.